Kamada (KMDA) director discloses multiple stock option grants

Rhea-AI Filing Summary

Dekel Benjamin, a director of Kamada Ltd., reported his holdings of stock options on Kamada’s ordinary shares. The filing lists four option positions, each covering 4,000 underlying ordinary shares at an exercise price of $6.2600 per share, with exercise dates on 2024-09-07, 2025-09-07, 2026-09-07, and 2027-09-07, all expiring on 2030-03-07. The options are exercisable using a net-exercise method, and the U.S. dollar exercise prices are translated from NIS using the Bank of Israel exchange rate as of March 13, 2026.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Dekel Benjamin

Role Director

Type	Security	Shares	Price	Value
holding	Options to purchase Ordinary Shares	--	--	--
holding	Options to purchase Ordinary Shares	--	--	--
holding	Options to purchase Ordinary Shares	--	--	--
holding	Options to purchase Ordinary Shares	--	--	--

Holdings After Transaction: Options to purchase Ordinary Shares — 4,000 shares (Direct)

Footnotes (1)

1. These options to purchase ordinary shares are exercisable using a net-exercise method All exercise prices presented in U.S. dollars represent a convenience translation from NIS based on the representative exchange rate of the Bank of Israel as of March 13, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dekel Benjamin

(Last) (First) (Middle)

12 GOTLIB ST.

(Street)

TEL AVIV L3 6439212

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
KAMADA LTD [ KMDA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase Ordinary Shares(1)	09/07/2024	03/07/2030	Ordinary Shares	4,000	$6.26(2)	D
Options to purchase Ordinary Shares(1)	09/07/2025	03/07/2030	Ordinary Shares	4,000	$6.26(2)	D
Options to purchase Ordinary Shares(1)	09/07/2026	03/07/2030	Ordinary Shares	4,000	$6.26(2)	D
Options to purchase Ordinary Shares(1)	09/07/2027	03/07/2030	Ordinary Shares	4,000	$6.26(2)	D

Explanation of Responses:

1. These options to purchase ordinary shares are exercisable using a net-exercise method

2. All exercise prices presented in U.S. dollars represent a convenience translation from NIS based on the representative exchange rate of the Bank of Israel as of March 13, 2026.

	/S/ Benjamin Dekel	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider position does Dekel Benjamin hold at Kamada (KMDA)?

Dekel Benjamin is reported as a director of Kamada Ltd. The filing shows his beneficial ownership in stock options on Kamada’s ordinary shares, without any open-market share purchases or sales disclosed in this document.

What stock options does Dekel Benjamin report holding in Kamada (KMDA)?

He reports four positions in options to purchase Kamada ordinary shares, each linked to 4,000 underlying shares. All have an exercise price of $6.2600 per share and an expiration date of March 7, 2030.

When can Dekel Benjamin’s Kamada (KMDA) options be exercised?

The options have staggered exercise dates on September 7 of 2024, 2025, 2026, and 2027. Each tranche covers 4,000 underlying ordinary shares and remains exercisable until expiration on March 7, 2030.

How are the exercise prices for Kamada (KMDA) options presented in this filing?

The exercise prices are stated in U.S. dollars at $6.2600 per share. A footnote explains these values translate from NIS using the Bank of Israel representative exchange rate as of March 13, 2026.

What exercise method applies to Dekel Benjamin’s Kamada (KMDA) options?

A footnote states the options to purchase Kamada’s ordinary shares are exercisable using a net-exercise method. This means fewer shares may be issued on exercise, after accounting for the exercise price through share withholding.

Does this Kamada (KMDA) filing show insider buying or selling of shares?

The document is an initial statement of option holdings and does not show any open-market purchases or sales. All entries relate to existing options to purchase ordinary shares, not common stock trades.